Pituitary Adenoma Clinical Trial

 

There are limited treatment options for pituitary adenomas outside of surgery, radiation and endocrine therapy. Recent data indicate that some pituitary adenomas can respond to chemotherapy, such as temozolomide (TMZ). Further, studies of other neuroendocrine tumors have shown that the addition of another chemotherapy agent, capecitabine (CAP), may allow better responses. This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. Patients are treated in 28-day cycles with both agents (up to six cycles) with MRI imaging completed after every two cycles, and they are followed closely for any potential side effects associated with treatment. This trial may be a good option for patients who cannot (or prefer not to) receive additional radiation therapy or surgery.

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas (TMZ-Cap)

 

Print